If you have ever wondered or were unable to determine the true cost of providing a prescritpion benefit to your employees; RxSense can help.

The RxSense Transparent Pharmacy Benefits Model

Why is it so difficult to determine my current drug benefit costs?

Other pharmacy benefit managers may keep hidden revenue streams that should be returned to the plan sponsor and intentionally make it difficult to see how they are really making their money. 

They try to sell value through high pharmacy discounts, low administrative fees, low dispensing fees and artificially inflated rebate payments, but pharmacy discounts, hidden mark-up or “spread” pricing, rebate earnings, and other pharmaceutical incentives may not be completely disclosed; leaving you guessing as to the real cost of your plan.

How is DataRx different?

Since the inception of RxSense, DataRx has endeavored to change the buying habits of the pharmacy benefits management industry.  Historically, PBMs were selected by comparisons that only evaluated a few components such as AWP discounts, dispensing fees and rebates, but these discounts and fees only represent a small portion of the total drug spend.  What matters most is the cost of each therapeutic category and the drugs that are actually being used.  By focusing on the drug mix and costs by therapeutic class, RxSense can help you maintained the lowest drug cost.

RxSense provides value in competitive pricing strategies, focus on the appropriate drug mix, and rebates where and when they make sense.

Why is transparency so beneficial?

The RxSense transparent pharmacy benefits model is fully aligned with the customer's goals and objectives.  We have eliminated the hidden mark-up or “spread” and do not retain rebates, network discounts, or incentives.  Our sole motivation is to maximize generic savings opportunities, select the lowest net cost brands in the formulary decision process, and implement other cost reduction strategies. 

Without the hidden revenue streams of the traditional model, our transparent pass-through model focuses on helping clients understand the industry and manage drug spending.  The complexity of the traditional model vanishes and a productive partnership is the net result.

What do the experts say about PBM transparency? 

For more information click the link below.

Dr. Mark Riley is considered to be one of the countries foremost experts on PBM abuses. Over the last decade many self-insured companies have seen their health care costs decline dramatically upon implementation of Dr. Riley's recommendations.